The company’s products are antibodies and peptide-therapeutics designed to modulate the immune response allowing it to exert its anti-cancer activity in an effective manner.

Our lead product, CT-011, is a humanized monoclonal antibody that interacts with PD-1, a B7 receptor-family-associated protein, and exhibits efficient anti-cancer immune response against a wide variety of mouse and human tumors. A Phase I clinical study in 17 patients with advanced hematological malignancies has been completed demonstrating that a single administration of CT-011 is safe and well tolerated. Despite the advanced stage of their disease, clinical responses were observed in 6 patients. 

A Phase II program has been initiated including 2 sponsored studies: the first, a Phase II clinical trial in patients with diffuse large B cell lymphoma that is ongoing in the US, Israel and India . The second is a Phase II study in patients with metastatic colorectal cancer that has been started in the US with additional locations in Europe and Asia to be opened. In addition to these 2 studies, several investigator-initiated studies are about to start with the first one in patients with relapsed follicular lymphoma to be conducted at the University of Texas, MD Anderson Cancer Center.